Developing first-in-class CD31xITAM bispecific antibodies for targeted immune modulation Tridek-One Therapeutics pioneers a platform of bispecific antibodies that agonize the CD31 ITIM inhibitory receptor to modulate cell-specific ITAM receptor activation for the treatment of a broad range of inflammatory and autoimmune diseases. The company’s lead program is a first-in-class CD31×GPVI bispecific antibody being developed for the treatment of thromboinflammatory diseases. This novel approach provides both antithrombotic and anti-inflammatory efficacy while minimizing bleeding risk, thereby addressing major critical medical unmet needs in the field. Our company is financed by leading European investors and led by an experienced management team. Santé, Healthcare, …

203 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Targeting iRhom2 for better treatment of autoimmune diseases SciRhom GmbH, based in IZB Martinsried, Germany, is a biotech start-up company that translates science into the preclinical and early clinical development of novel biopharmaceuticals for the treatment of life-threatening diseases. Founded in late 2016, we develop first-in-class antibodies against iRhom2, a key modulator of several crucial pro-inflammatory signalling pathways, including TNF-alpha signalling. Following the preclinical and early clinical development of these monoclonal antibodies, we are aiming to provide superior treatment options to currently existing inhibitors of TNF-alpha signaling. SciRhom is poised to transform the lives of patients with autoimmune diseases. drug …

88 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Advancing Glycan Mediated Therapy GlycoEra is developing biologics to selectively target the root cause of many autoimmune diseases: a specific circulating protein (autoantibody). Our approach enables us to degrade targets rapidly, selectively, and deeply while avoiding broader dampening of the immune system. This offers many potential benefits over existing broad-spectrum immune-suppressing therapies, including an improved safety profile and the potential for earlier disease intervention – which could improve patient quality of life, limit long-term complications and lower overall healthcare costs. Our best-in-class, extracellular degrader BiNDTM platform (Biologic Natural Degrader), allows us to target and rapidly, deeply degrade any circulating protein …

208 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Developing first-in-class therapies designed to defeat chronic inflammation and fibrosis at the source. Our innovative therapeutic approach targets upstream amplifiers of disease offering potential treatments across a diverse array of therapeutic indications. Calluna Pharma is a clinical stage biotech company driven by a commitment to improve patient outcomes in diseases where existing treatments are sub-optimal. We believe in the power of immunology to push boundaries, challenge the status quo, and develop therapies that will make a real difference for people living with serious diseases.

202 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Changing the paradigm of osteoarthritis treatment! CartilaGen Inc. is developing an intra-articular injection of a small-molecule drug capable of preventing post-traumatic osteoarthritis. CartilaGen's solution aims to provide an unprecedented disease-modifying treatment to an area of medicine that remains an unmet medical need. Osteoarthritis, Biomaterials, and Preventative Medicine

111 similar entities Type: Startup Activities: biotech deeptech healthtech Technologies: Synthetic Biology

Vivet Therapeutics is dedicated to developing innovative gene therapy treatments for orphan diseases. Vivet Therapeutics is focused on optimizing gene therapy through collaborating with the Fundacion para la Investigacion Medica Aplicada (CIMA, Universidad de Navarra) to develop new AAV vectors specifically targeting the liver and generating new technologies to optimize gene delivery and long term expression. Gene Therapy

96 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Pioneering RNA cell therapy for autoimmune disease Cartesian Therapeutics is a clinical-stage company pioneering cell therapy for the treatment of autoimmune diseases. The Company’s lead asset, Descartes-08, is a CAR-T in Phase 3 clinical development for patients with generalized myasthenia gravis with plans to initiate a Phase 2 trial in myositis. For more information, please visit www.cartesiantherapeutics.com. Immunotherapy, Oncology, Molecular Biology, Immunology, Myasthenia Gravis, ARDS, Cell Therapy, NETs, Gene Therapy, Cancer Research, multiple myeloma, SLE, mRNA, CAR-T, Systemic lupus erythematosus, Autoimmunity, Autoimmune Disease, and Lupus

293 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Leading the Next Frontier of Cell Therapy Sonoma Biotherapeutics is a South San Francisco and Seattle-based clinical-stage biotechnology company developing engineered regulatory T cell (Treg) therapies to treat serious autoimmune and inflammatory diseases by restoring balance to the immune system. Founded by pioneers in Treg biology and cell therapy, the company brings together leading expertise and proprietary methodologies for the discovery and development of disease modifying and curative therapies. Sonoma Bio has initiated two Phase 1 studies to evaluate the safety and proof-of-mechanism of the company’s lead Treg cell therapy candidate, SBT-77-7101, in patients with rheumatoid arthritis and hidradenitis suppurativa. …

129 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Life-Transforming Therapies - Developing novel therapeutics for serious rare conditions Therachon is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative treatments for severe, rare conditions for which there is significant unmet medical need. We are currently advancing a pipeline of therapeutics focused on rare gastrointestinal and musculoskeletal disorders and conditions. Our lead product candidate, apraglutide, is a second generation, potentially best-in-class, synthetic peptide analog of glucagon-like peptide-2, or GLP-2, that is being evaluated in two Phase 2 clinical trials for the treatment of patients with short bowel syndrome, or SBS, a malabsorption disorder caused …

110 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Valora Therapeutics is a privately held biotech, co-founded with Carolyn Bertozzi, developing multispecific antibodies and T cell engagers that break the glyco-immune checkpoint. Our proprietary AbLecTM and T-LecTM platforms combine precise tumor targeting with localized glyco-immune checkpoint disruption to generate therapeutics with superior anticancer activity without the requirement for delivering toxic payloads. Valora's discovery engine was built on a $30M Seed Round led by Avalon BioVentures.

185 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Translating ET biology into novel therapies for immune-mediated inflammatory diseases Citryll has translated a deep understanding of the extracellular trap (ET) pathway to therapeutically address its central role in a broad range of immune-mediated inflammatory diseases (IMIDs). With a unique dual mode of action, the company’s lead antibody, CIT-013, has reached the clinic by demonstrating a precise and powerful ability to control ETs and ETosis. Citryll is initially developing CIT-013 as a novel drug for rheumatoid arthritis and hidradenitis suppurativa, which may serve as enabling indications for a wide spectrum of IMIDs. Immunology, Therapeutics development, Neutrophil Extracellular Traps, Inflammatory diseases, …

73 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Vicore Pharma is a clinical-stage biopharmaceutical company unlocking the potential of a new class of drugs with disease-modifying potential in respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). The company’s lead program, buloxibutid, is a first-in-class oral small molecule angiotensin II type 2 receptor agonist, which has received Orphan Drug and Fast Track designation from the United States Food and Drug Administration and is currently being investigated in the global 52-week Phase 2b ASPIRE trial in IPF. Vicore is publicly listed on the Nasdaq Stockholm exchange with the ticker VICO. pharmaceutical development

78 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Reimagining known biology to deliver high impact medicines Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline includes three clinical-stage development programs including an allosteric BCR-ABL inhibitor, a small-molecule GLP-1 receptor agonist, a THR-β agonist and preclinical GIPR modulator programs. For more information, please visit: www.ternspharma.com. Pharmaceuticals, Liver Disease, Life Sciences, BioPharmaceuticals, CML, Oncology, and HemOnc

343 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Discovery of novel immune checkpoint inhibitors for cancer immunotherapy OREGA Biotech specializes in the discovery and the development of first-in-class monoclonal antibodies for cancer immunotherapy. The company was incepted in 2010 and is managed by Jeremy Bastid, CEO and Gilles Alberici, President. The science at OREGA Biotech is based on the research conducted by its academic cofounders Nathalie Bonnefoy, Armand Bensussan and Jean-François Eliaou. Our in vivo screening approach aims at discovering and validating novel immune checkpoint inhibitors and regulators of anti-PD1 response. Our lead asset, an anti-CD39 monoclonal antibody, has been out-licensed to Innate (2016) Pharma and then partnered …

209 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

For every therapeutic challenge, we question traditional assumptions and find better solutions. VYNE Therapeutics is a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immunological (I&I) conditions with high unmet need. Led by a proven and resourceful team of drug developers, VYNE is applying scientific innovation to advance novel therapies that have the potential to improve the lives of millions of people afflicted by autoimmune diseases. The catalyst of the company’s differentiated approach is its proprietary InhiBETTM Platform that potentially unlocks a promising new drug target for improving the treatment of challenging I&I diseases with …

90 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

The clinical-stage biotech company advancing novel antigen modulation treatments for cancer and autoimmune diseases. Many diseases are caused, or resist treatment, because T cells can't recognize or target cells correctly.​ Our first-in-class small molecules are developed to control T cell activation by modulating antigen presentation, altering how cells appear to the immune system so it can recognize and target them correctly. Our oncology treatment (GRWD5769) is delivering promising Phase 1/2 data in patients with solid tumors, demonstrating a strong safety and tolerability profile, as well as generating meaningful clinical activity. Our autoimmunity treatment (GRWD0715) is progressing in a Phase 1/2 …

104 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

We are on a global mission to establish gene therapy as a new standard of care for the leading causes of vision loss. Adverum Biotechnologies (NASDAQ: ADVM) is a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases with the aspiration of developing functional cures to restore vision and prevent blindness. Leveraging the research capabilities of its proprietary, intravitreal (IVT) platform, Adverum is developing durable, single-administration therapies, designed to be delivered in physicians’ offices, to eliminate the need for frequent ocular injections to treat these diseases. Adverum is evaluating its …

75 similar entities Type: Startup Activities: deeptech healthtech Technologies: Synthetic Biology

Developing a next generation, immunomodulatory treatment, for mild to moderate atopic dermatitis. Pharmability originated from a pivotal scientific discovery made at the Karolinska Institutet, where Professor Anna-Lena Spetz uncovered the unique immunomodulatory potential of a single-stranded oligonucleotide, now known as TIR-01. Unlike conventional therapies that broadly suppress the immune system, TIR-01 demonstrated the ability to modulate immune responses with precision, laying the groundwork for a new class of treatments for autoimmune and inflammatory diseases. This novel mechanism of action opened the door to developing safer and more targeted therapies, an approach that has become central to TIRmed's mission. Since its …

62 similar entities Type: Startup Activities: deeptech biotech

The KELTICPharma team combine academic innovation, deep target knowledge and corporate drug discovery expertise. In 2019 Prof Andrew Tobin published validation of PfCLK3 as a target with breakthrough potential in the treatment of malaria. Successful drug development would provide a single medicine that is curative, transmission blocking and prophylactic.

202 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Dedicated to develop the medicines of the future VeonGen Therapeutics (formerly known as ViGeneron) was founded in 2017 as a spin-off of the Ludwig-Maximilians-University (LMU) Munich. At VeonGen Therapeutics we are dedicated to develop innovative gene therapies based on our two unique and proprietary technology platforms. VeonGen Therapeutics will leverage its two technology platforms to address unmet medical needs with in-house gene therapy programs for selected retinal disorders. Together with partners we will exploit our VeonGen Therapeutics technologies for additional indications. Gene Therapy, Inherited Retinal Disorders, and AAV vector

62 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Multilineage immune modulation. The next chapter in autoimmune diseases. Mysthera is a preclinical stage biotech start-up focused on developing first-in class, oral therapeutics to treat major unmet needs in autoimmune diseases. Our unique approach has potential to transform patient lives in a number of disease settings including glomerulonephritis, rheumatoid arthritis and inflammatory bowel disease. We are first to develop PIM kinase inhibitors as therapeutics for multi-lineage immune cell driven autoimmune diseases. The team are experts in PIM kinase and immunology. Mysthera was founded by Forty51 Ventures in Europe’s pharma/biotech hub, Basel, in Switzerland in early 2023. biotech, kinase inhibitors, autoimmune …

97 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Our rational design approach in therapeutics offers a paradigm shift in disease, making the untreatable, treatable. We're pioneering a new era in drug design and development with rationally designed medicines leveraging human capabilities in advanced chemistry and biotech advancements. Our approach centers around biomimicy selectively targeting central cascades that drive disease. Our lead program is in development in kidney disease and has the potential to modify disease outcomes for millions of patients.

168 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

First-in-class immunomodulatory peptides. Evora Biosciences develops novel immunomodulatory peptides with the aim to bring first-in-class treatments to patients in areas of high unmet need. immunodermatology, peptides, inflammatory diseases, respiratory diseases, inflammation, and immunomodulation

87 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Exceptional Human Antibody Discovery Technology Trianni, Inc. is a biotech company specializing in human antibody discovery platform technology. We offer the leading in vivo platform enabling efficient discovery of fully-human monoclonal antibodies. The Trianni Mouse offers biologic drug discoverers a best-in-class solution for the isolation of therapeutic antibody candidates. Benefits over older conventional mouse immunization + humanization approaches include superior lead panels with respect to potency and diversity along with speed to the clinic and lower operating costs. We aim to make Trianni’s premium technology available to any Pharma or Biotech company engaged in antibody discovery by offering flexible licenses …

77 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Fighting chronic and fatal diseases Tirecat Health is a company developing a family of novel polymers with amazing potential in the healthcare field. We are propelled with purpose to fight chronic and fatal diseases affecting patients worldwide using our revolutionary technology to improve their quality of life. In order to make this purpose a reality, the company is preparing to move towards the clinical phase to demonstrate the astonishing results seen in preclinical trials.

300 similar entities Type: Startup Activities: healthtech deeptech Technologies: Synthetic Biology

Safer, more effective ADCs and protein-drug-conjugates with GoldenSiteTM technology VALANX has built GoldenSite, a site-specific conjugation platform that places ADC payloads in structurally shielded positions on the antibody, delivering significantly reduced off-target interaction while preserving and enhancing efficacy. Using GoldenSite, we are developing a LIV-1 targeting, differentiated ADC intended to treat metastatic triple-negative-breast cancer. Bioconjugation, Site-specific conjugation, PEGylation, Biotechnology, Research and Development, ADCs, Novel format conjugates, Radioconjugates, Next generation bioconjugates , and Site-agnostic conjugation

87 similar entities Tags: H2020 Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

From Microbes to One Health. Taylor made R&D to tackle infectious diseases. Vibiosphen is a SME healthcare biotechnology in infectious diseases founded in 2014. Given the important and interdependent human, animal, and environmental dimensions of antimicrobial resistance, the One Health concept promotes a global effort to achieve the best health for people, animals, and the environment. In this context, Vibiosphen takes part of the efforts that are underway to develop new anti-infective therapies, to rejuvenate the antibiotic pipeline, develop novel antibiotics, and discover innovative therapeutic strategies for priority pathogens. Based on its pluridisciplinary and integrated approaches, Vibiosphen, with more than …

63 similar entities Type: Startup Activities: biotech deeptech manufacturing Technologies: Synthetic Biology

Building the Future of Precision Medicines through V-Body, RNA and In Vivo Cell Engineering Platforms. At Valerio Therapeutics, we are pioneering a new generation of precision therapies to tackle complex and underserved diseases. Our proprietary V-Body platform is based on two fully synthetic single-domain antibody (sdAb) libraries, derived from a human VH and a fully humanized VHH. Engineered for optimal performance, this ultra-small sdAb platform (~15 kDa) surpasses the limitations of current treatments by enabling deep tissue penetration and highly precise therapeutic delivery, ensuring superior efficacy and target engagement. Our approach integrates innovative target identification using advanced predictive models, antibody …

227 similar entities Type: Startup Activities: biotech deeptech manufacturing Technologies: Synthetic Biology

Innovation. Applied. Founded in 2021, POLYGON Therapeutics is a Paris-based biotechnology company developing precision cardio-immunology therapies targeting inflammatory drivers of cardiovascular disease. The company combines translational human biology, biomarker-driven development and immunology expertise to develop novel therapeutic approaches in cardiovascular disease.

228 similar entities Type: Startup Activities: biotech deeptech healthtech Technologies: Synthetic Biology

Immuno-Oncology and Immuno-Inflammation - Breakthrough Immuno-Science for Patients OSE Immunotherapeutics, a biotech dedicated to developing first-in-class assets in immuno-oncology (IO) & immuno-inflammation (I&I). • Tedopi® (therapeutic cancer vaccine): Registration Phase 3 in 2nd-line NSCLC in HLA-A2+ patients with secondary resistance. Phase 2 trials, sponsored by onco groups, of Tedopi® in combo in solid tumors. • Lusvertikimab (mAb IL-7R antagonist); Positive Phase 2 in UC; preclinical research in ALL. • OSE-279 (anti-PD1): 1st positive results in Phase 1/2 in solid tumors. • FR-104/VEL-101 (anti-CD28 mAb): developed in partnership with Veloxis in transplant; Phase 1/2 in renal transplant (CHU Nantes); successful Phase …

188 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Transforming lives by accelerating innovation in cardiometabolic health Verdiva Bio is committed to developing next-generation therapies to help people living with obesity, cardiometabolic disorders, and related complications achieve better outcomes via more patient-friendly therapeutic options. Our most advanced therapy is VRB-101, an oral GLP-1 peptide in clinical development that has demonstrated best-in-class efficacy potential in a phase 1 study in Australia, which also confirmed the viability of once-weekly dosing. We are also developing a portfolio of amylin molecules, including oral and subcutaneous agonists, and other undisclosed programs that offer the potential for enhanced efficacy, improved tolerability, and healthier weight loss. …

120 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

A New Hope for Hemorrhagic Stroke Op2Lysis develops new treatments for patients suffering from thrombosis at the cerebrovascular level, with an initial focus on the hemorrhagic form of stroke. Indeed, there is no currently approved and available therapeutic solution for these patients. The company develops its game-changing NANOp2Lysis platform, associating a breakthrough vectorisation technology, industrial know-how enabling clinical quality production, and preclinical expertise to propose predictive and translational models, a first in this field. O2L-001, the first product resulting from this technology, will soon enter regulatory toxicology with the aim of applying for clinical trial authorisation in patients in North …

234 similar entities Type: Startup Activities: biotech deeptech healthtech Technologies: Synthetic Biology

ARTiDe aims to generate an antigen-specific cellular therapy for type 1 diabetes for a future clinical trial. Autoantigen-specific Regulatory T cell therapy against Type 1 Diabetes (ARTiDe) will make a unique contribution to the understanding of autoimmunity in humans and the development of antigen-specific immunotherapy. ARTiDe has the ambition to take the lead in the restoration of long-lasting immune tolerance in Type 1 Diabetes (T1D) patients, aiming to provide a cure for this disease. Funded by the European Union under Grant Agreement No 101080823

60 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Better Delivery. Better Medicines. Precision Intradermal Therapeutics. Gylden is a clinical-stage, privately held biotechnology company, headquartered in Abingdon, Oxfordshire, UK, with R&D and GMP manufacturing facilities in Milton Park, Oxfordshire, UK, an operating subsidiary in Doylestown, Pennsylvania, USA and a manufacturing facility in Fremont, CA, USA. The Company is pioneering the development of synthetic T cell-priming vaccines/immunotherapies designed to mimic the body’s natural cellular immune response to destroy and clear pathogen-infected cells to protect against some of the world’s most urgent health threats. The candidates are designed for delivery via novel skin immunisation into the epidermal layer, aiming to ease …

69 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Digital bio-solutions designed to support the development of biomedicines and optimize their prescription. mYXpression is an innovative French company positioned in the field of health innovation. The company, specialized in R&D, develops innovative tools to assist in the prescription of biomedicines. Its first tool, the RITI® RA test, provides a personalized report specific to the patient by indicating an efficacy score for each biotherapy. This brand new approach provides numerous useful insights to the doctor by assisting in the prescription of biotherapy in order to increase the patient's chances of remission. bio-numérique, innovation technologique, big data, bio-technologie , biotherapie, intelligence …

189 similar entities Type: Startup Activities: biotech deeptech healthtech Technologies: A.I.

Mersana Therapeutics is now a part of Day One Biopharmaceuticals. For more information visit: https://www.dayonebio.com At Mersana, we have a passion for advancing therapies to make a significant impact in the lives of people living with cancer. Mersana Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel antibody-drug conjugates (ADCs) and driven by the knowledge that patients are waiting for new treatment options. The company has developed proprietary cytotoxic (Dolasynthen) and immunostimulatory (Immunosynthen) ADC platforms that are generating a pipeline of wholly-owned and partnered product candidates with the potential to treat a range of cancers. Its pipeline …

135 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Mironid Limited is an innovative new drug discovery company that develops proprietary drug candidate molecules by modulating the activity of key cell signalling proteins. This allows us to access multiple therapeutic areas for exploitation. Our lead programme is in the area of rare genetic kidney disease.

150 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Biopharmaceutical company focused cardiometabolic and inflammatory diseases Veru is a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases. The Company’s drug development program includes two late-stage novel small molecules, enobosarm and sabizabulin. Enobosarm, a selective androgen receptor modulator (SARM), is being developed as a next generation drug that makes weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass thereby improving body composition and physical function. Sabizabulin, a microtubule disruptor, is being developed for the treatment of inflammation in atherosclerotic cardiovascular disease.

111 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

AB Science was founded in 2001 by a team of researchers, clinicians and entrepreneurs who have dedicated their lives to discover key mechanisms in life science and develop new drugs targeting these mechanisms to dramatically change the life of patients in the most unmet medical needs. We are innovators and scientific entrepreneurs in the field of life science. Our group is specialized in targeted therapies through tyrosine kinase inhibitors for treating diseases with high medical needs in the field of cancers, chronic inflammatory diseases and neurological degenerative disorders. Our pipeline is both in Human and Veterinary medicine. Our drugs are …

370 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Phialogics state of the art platform transforms native proteins into powerful therapeutics. Phialogics is developing a pipeline of bi-functional, bi-specific and multi-specific molecules to treat autoimmune diseases. Our unique First-in-Class immunomodulatory approach has a proof of concept in several translational in vivo models as well as in patient-derived materials ex vivo.

91 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Reinventing Cancer Immunotherapy Valo Therapeutics (ValoTx) is a developer of novel immunotherapies in cancer and infectious disease. Our unique approach to immunotherapy, based on oncolytic viruses and viral vectors combined with disease-specific peptides, delivers highly adaptable and immunogenic therapeutic vaccination platforms. A spin-out company from the University of Helsinki, Finland, Valo Tx has assembled a talented team of immunotherapy experts, who together with the founding scientists have the necessary expertise to take its patented technology through clinical development and make it available to patients. The management team has a proven track record of developing successful companies from a laboratory idea …

188 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Transforming lives with groundbreaking treatments Coultreon Biopharma's mission (formerly Onco3R Therapeutics) is to develop life-changing medicines for patients affected by chronic inflammatory diseases of high unmet medical needs. The team is leveraging their knowledge and expertise to bring transformative innovations to patients suffering from auto-immune diseases. In this field, there is an urgent need for more convenient oral drugs that can offer greater efficacy with a better safety profile. Drug Discovery, Drug Development, Immunology, Biotech, and R&D

826 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Better Technology. Better Delivery. Developing a new generation of disease-modifying therapies. Driven by our proprietary Enhanced Delivery Oligonucleotide (EDO) platform, we are creating a pipeline of disease-modifying therapeutics with the potential to safely and effectively target the root cause of serious genetic neuromuscular and neurological disorders. Biotechnology, Chemistry, Biology, Bioscience, Life sciences, and Therapeutics

296 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Development of covalent small molecules to transform the treatment of autoimmune and inflammatory disorders ARTICA Therapeutics and its seasoned team started operatons in 2020 and was supported by pre-Seed financing from BioGeneration Ventures. Artica is dedicated to developing novel small molecule medicines for inflammatory and autoimmune indicatons. Artca is at the forefront of covalent binding technology as well as in label-free cellular-based screening approaches. The unique combinaton of these capabilities allows rapid progression of the best drug candidates that have unprecedented and superior characteristics, creating novel and highly selective therapies for patients with unmet medical need.

71 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Innovative therapeutic procedures for Intensive Care Medicine for the treatment of severe infections / sepsis ARTCLINE GmbH develops innovative therapy methods for intensive care medicine based on immune cells. Our current main project is the development of the so-called ARTICE technology for the treatment of bacterial sepsis. ARTCLINE's vision is the development of innovative immune cell-based therapy approaches and to make the technology available to physicians and hospitals worldwide. The safety and effectiveness of the therapy is our top priority. Our extensive cell biological, clinical and industrial experience in the fields of immunology, sepsis diagnostics and therapy help us to …

94 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Pioneering first-in-class, small-molecule therapies for immune-mediated and oncologic disorders We are a clinical-stage biotechnology company combining courage, conviction and cutting-edge science to develop breakthrough treatments for immune-mediated and oncologic disorders, with the hope of helping patients overcome their disease and live a better life. We are pioneering first-in-class, small-molecule therapies that harness master regulators of cellular function and inhibit multiple drivers of disease via a single target. In modulating the function of profound intracellular regulators, our medicines have the potential for significant clinical impact in the most difficult-to-treat diseases. We believe the wide-ranging impact of our therapeutic platforms can be …

435 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

ILC Therapeutics is a specialist UK-based developer of hybrid interferons, a new engineered drug class with improved therapeutic profiles, enabling broad applications across multiple indications. Hybrid interferons combine favourable attributes of specific natural interferon sub-types to produce novel drug candidates designed to deliver reduced toxicity and improved efficacy. ILC Therapeutic’s platform approach has produced two first-in-class lead candidates, AlfacyteTM and DermacyteTM focused on antiviral and dermatological indications respectively, which are progressing towards the clinic.

64 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Leveraging science and innovation to accelerate the development of next-generation antibody therapeutics. AAX Biotech AB is a biotech company spun out from Karolinska Institutet by co-founders Mats AA Persson and Daniel X Johansson. We specialize in next-generation antibody therapeutics through our two unique and proprietary technologies, SeqitopeTM and Opti-mAbTM, that enable high-resolution and high throughput epitope mapping as well as stabilization of single chain variable fragments (scFv) for applications such as bispecific antibodies and CAR-T cells. Our team is made up of highly qualified experts, all with PhDs in relevant fields. Our mission is to innovate and solve unmet needs …

144 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Oral Delivery . Genetic Breakthroughs We are a preclinical-stage biotech company focused on developing revolutionary therapies to address Inflammatory Bowel Diseases. Harnessing the unique capabilities of our Genetic Medicines Oral Delivery platform we aim to overcome major limitations of current treatments and unlock the groundbreaking potential of Genetic Medicines in IBDs, driving transformative change in a field with critical medical needs.

92 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

First-in-class therapeutics for autoimmune disorders We develop first-in-class biologics for several underserved autoimmune conditions. Our therapeutic approach aims to preserve and re-establish organ cell function, transforming the treatment paradigm for intractable autoimmune diseases

117 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Collaborating with NIH & DoD to develop treatment options, targeting unmet needs in three multi-billion dollar markets. Virpax is pioneering advanced healthcare solutions with Probudur, its flagship product leveraging proprietary liposomal encapsulation. Designed for sustained release, Probudur delivers local anesthetic at the wound/incision site, effectively managing post-operative pain for an extended 96 hours. Collaborating through Cooperative Research and Development Agreements (CRADA) and partnering with prestigious institutions like the National Institute of Health/NCATS and U.S. Army Institute of Surgical Research/Department of Defense, we are committed to developing non-addictive treatments. Additionally, our involvement in the Epilepsy Therapy Screening Program (ETSP) underscores our …

145 similar entities Type: Startup Activities: biotech deeptech healthtech manufacturing Technologies: Synthetic Biology

At FairJourney Bio, we specialize in cutting-edge antibody discovery and development, offering end-to-end solutions that fast-track your research. With over a decade of expertise, our innovative technologies and seasoned team have successfully advanced 19 antibodies to clinical stages. Our adaptable partnership model empowers projects of any scale, fostering collaboration and breakthrough innovation. Whether you're in early-stage research or development, we deliver tailored, high-quality antibodies designed to meet your specific needs. Join us in revolutionizing therapeutic discovery and making lasting impacts on global healthcare. Monoclonal antibodies, Antibody humanization, Antibody production, Antibody affinity maturation, Phage display libraries, Mammalian Display, Naïve Libraries, VHH …

193 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Leading the creation of transformative, first-in-class anti-infectives for life-threatening respiratory infections Aridis Pharmaceuticals is a late-stage clinical development company leading the creation of transformative, first-in-class anti-infectives for life-threatening respiratory infections. The company’s pipeline of novel mechanism antibacterial and antivirals, sprung from its proprietary technology platforms, are designed to combat the growing public health threat of antimicrobial resistant bacteria (AMR). Monoclonal Antibody , Infectious Disease, Cell line Engineering, Inhalation therapy

147 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Technology-driven biotech with an AI-powered miniprotein RnD platform VRG Tx is technology-driven biotech with a drug discovery platform that integrates AI with wet lab processes to develop next-generation therapeutics. Our vision is to cure diseases through previously undruggable targets and inaccessible mechanisms of action. medicinal biotechnology, research, immunology autoimmune deases , translational health research, use of genetic engineering in medicine, anti cancer drug discovery, oncological drugs, autoimmune diseases, translational research, peptide, cellandgenetherapy, and genetherapy

589 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Pioneering Antibody Innovations to Defeat Cancer At VERAXA Biotech (NASDAQ:VRXA), we are building a premier engine for the discovery and development of next-generation antibody-based therapeutics, including antibody-drug conjugates (ADCs), bispecific T cell engagers (BiTAC TCEs), and other innovative formats. Powered by a suite of transformative technologies and guided by rigorous quality-by-design principles, we are rapidly advancing our pipeline of ADCs and proprietary BiTAC formats into clinical development and beyond. VERAXA Biotech was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), a world-renowned institution known for pioneering life science research and cutting-edge technologies. Cancer Research, Drug Development, …

192 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Targeting diseases at their molecular roots Vivoryon is a clinical stage biotechnology company focused on developing innovative small molecule-based medicines for the treatment of inflammatory and fibrotic disorders of the kidney. Driven by its passion for ground-breaking science and innovation, the Company strives to improve patient outcomes by changing the course of severe diseases through modulating the activity and stability of pathologically relevant proteins. Vivoryon’s most advanced program, varoglutamstat, a proprietary, first-in-class orally available QPCT/L inhibitor, is being evaluated to treat diabetic kidney disease.

84 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Elevating surgical planning with advanced flow simulations. Redefining the fronteries in surgery and medical research... At VirTest we are focused on personalized medicine developing computational models, in-silico simulations and image processing solutions to assist clinicians and medical device companies in conducting product testing, facilitating decision making and improving outcomes. With our first solution VIDAA, we enable a comprehensive understanding of device behavior before any intervention occurs. Based in Barcelona, from the Universitat Pompeu Fabra.

108 similar entities Type: Startup Activities: deeptech healthtech biotech Technologies: Synthetic Biology

Living Immunotherapies Medigene AG (FSE: MDG1) is a leading immuno-oncology platform company dedicated to developing T-cell therapies to effectively eliminate cancer. Its end-to-end technology platform is built on multiple proprietary exclusive product development and product enhancement technologies, and allows Medigene to create best-in-class differentiated, T cell receptor engineered T cell (TCR-T) therapies for multiple solid tumor indications that are optimized for both safety and efficacy. This platform provides product candidates for both its in-house therapeutics pipeline and partnering. For more information, please visit www.medigene.com Immunotherapies and T Cell receptors TCR

85 similar entities Type: SMB Activities: deeptech biotech Technologies: Synthetic Biology

Developing novel medicines for patients with difficult-to-treat cancers and other serious diseases. Zymeworks is a global biotechnology company developing and managing a portfolio of differentiated biotherapeutics to improve the standard of care for patients with difficult-to-treat cancers and autoimmune diseases. Leveraging our proprietary antibody engineering platforms, we are advancing a diverse pipeline of multispecific antibodies and antibody-drug conjugates, alongside partnered programs including Ziihera® (zanidatamab-hrii). Our integrated R&D engine and strategic partnerships enable the novel design of next-generation antibody therapeutics addressing significant unmet medical need. antibody therapeutics, bispecific antibodies, ADC, Breast Cancer, Gastric Cancer, protein engineering, Biliary Tract Cancer, autoimmune diseases, …

116 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology